With most glimmers of hope extinguished in the third quarter, 2022 is shaping up to be an annus horribilis for sector share prices.
Astrazeneca and Ionis’s discontinuation could herald a nervous time for others in this space.
Hopefully the acquisition of Global Blood Therapeutics will go better than Pfizer’s last foray into sickle cell deal-making.
Asset prices fall sufficiently to persuade Roche to sign up to Poseida’s allogeneic cell therapies.
Updated data with exa-cel in sickle cell disease and beta-thalassaemia could put the fear into competitors.